David Johnson

David Johnson was the Founder and CEO of VelosBio, which was acquired by Merck in 2020. Prior to this, Mr. Johnson was the CEO of Acerta Pharma, up until its acquisition by AstraZeneca. He has served in various roles at Hoffmann-La Roche, Immunex (acquired by Amgen), Millennium (acquired by Takeda), Favrille, Gloucester (acquired by Celgene), and Calistoga (acquired by Gilead).